Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Martek plans offsets for formula contracts

This article was originally published in The Tan Sheet

Executive Summary

Martek Biosciences CEO Steve Dubin says the nutritional oils firm will offset price reductions in extended infant formula supply contracts with Mead Johnson and Danone through formula market growth, new production technologies and expansion of its Amerifit Brands business. Dubin said during an earnings call Sept. 1 that Amerifit will launch five to seven supplement stock-keeping units in 2011 (1"The Tan Sheet" Aug. 16, 2010). Martek reported cost reductions in life'sDHA and life'sARA production, and efficiencies from Amerifit - acquired in January - helped swell its third-quarter gross margin to nearly 50 percent from 44 percent in the year-ago period. Dubin said he expects further margin, revenue and earnings growth in 2011. The Columbia, Md.-based firm recorded net sales of $114 million in the May-July timeframe, a 51.9 percent increase

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel